Data from two European trials — a real-life study in Italy, and a long-term Czech trial looking at impact on cognition — supported the efficacy of a widely approved cannabinoid spray in treating moderate to severe spasticity (muscular stiffness or involuntary spasms) in multiple sclerosis (MS) patients who failed to benefit from other spasticity treatments.
Sativex, developed by GW Pharmaceuticals, is a formulated extract of the cannabis sativa plant, whose principal components are delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD) in a 1:1 ratio. The medication is approved in about two dozen countries — mostly across Europe but also in Canada, Israel, and Australia — as an add-on treatment to other anti-spasticity medications, like baclofen and tizanidine. It is not approved for MS patients in the U.S.
An oromucosal spray, Sativex is absorbed through the lining of the mouth.
The observational, ongoing trial